Intrinsiqq
Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc.

HEPA

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$13M
EPS$1.19
P/E0.09
P/FCF-6.60
EV/EBITDA-2.35
FCF Yield–
Div. Yield–
Net Debt/FCF1.8x
Hepion Pharmaceuticals, Inc. intrinsic value
52-Week Range
$0.04$0.18

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$7M

▲ +37.3% YoY

Op. Margin

–

ROIC

-202.02%

▲ +177.2pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$2M

▲ +82.0% YoY

Op. Cash Flow (TTM)

-$2M

▲ +82.0% YoY

Net Debt

-$4M

Net Cash Position

Cash & Equiv.

$4M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with HEPA

CompareIntrinsic value
SKVISkinvisible Inc.
$0.18+0.00%0
PMHSPolomar Health Services Inc.
$0.15+45.00%30
TCRTAlaunos Therapeutics Inc.
$1.66+4.40%10
PULMPulmatrix Inc.
$1.28-10.21%40
OTLCOncotelic Therapeutics Inc.
$0.01+22.00%10
GTBPGT Biopharma, Inc.
$2.96-6.92%20
DAREDare Bioscience Inc.
$0.41-9.96%10
PTNPalatin Technologies, Inc.
$4.58-7.10%10

Hepion Pharmaceuticals (HEPA) in three numbers

Quality score
20/100
Best check: net debt, -$4M. Weakest: return on capital, -202.0%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
0.09
Price to free cash flow -6.60.
Financials

Questions about Hepion Pharmaceuticals

Is Hepion Pharmaceuticals (HEPA) overvalued?

Hepion Pharmaceuticals trades at 0.09 times earnings. Intrinsiqq's fair value calculator has no opening value for HEPA, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.

Is Hepion Pharmaceuticals a high-quality business?

Hepion Pharmaceuticals scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is net debt at -$4M, and its weakest is return on capital at -202.0%. The Quality tab shows every check against its target.

Does Hepion Pharmaceuticals (HEPA) pay a dividend?

No. Hepion Pharmaceuticals (HEPA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 8 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in HEPA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing HEPA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.